This research agreement is to test and determine the effect of AAGP on monoclonal antibody production and bone marrow recovery.
UBC's antibody lab will test whether AAGP enhances the production of monoclonal antibodies from cell lines, an important manufacturing issue for current immunotherapies.
UBC will also test whether AAGP enhances the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy.
The goal will be to determine whether AAGP enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation.
ProtoKinetix has developed and patented a family of hyper stable, potent glycopeptides that enhance both engraftment and protection of transplanted cells used in regenerative medicine. The University of Alberta has begun Phase 1 human clinical trials.
Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date including diabetes, retinal degeneration, cardiac repair, and other degenerative conditions.
In addition, The company is studying the potential impact on several cancer therapies.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment